GlassScriptPhysician profile
Arlene M Fedorchak
NPI 1891998340
$4,971.05
in general payments reported to CMS, 2019-2025
38 companies · $776 in 2025
The $776 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $297 · 2021: $886 · 2022: $905 · 2023: $904 · 2024: $948 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,628.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,069.39 | 2020-2025 | |
| Novo Nordisk INC | $658.07 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $444.54 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $411.75 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $370.09 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $365.49 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $245.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $192.84 | 2022-2025 | |
| Abbott Laboratories | $94.70 | 2022-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.59 | 2022-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $86.41 | 2021-2023 | Trintellix |
| Amarin Pharma, INC. | $86.05 | 2020-2021 | |
| Astellas Pharma US INC | $81.57 | 2023-2025 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company LTD. | $81.31 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $79.48 | 2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arlene Fedorchak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.